|
1
|
Daniels MG, Bowman RV, Yang IA, Govindan R
and Fong KM: An emerging place for lung cancer genomics in 2013. J
Thorac Dis. 5 (Suppl 5):S491–S497. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Singhal S, Miller D, Ramalingam S and Sun
SY: Gene expression profiling of non-small cell lung cancer. Lung
Cancer. 60:313–324. 2008.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pao W and Girard N: New driver mutations
in non-small-cell lung cancer. Lancet Oncol. 12:175–180.
2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Bronte G, Rizzo S, La Paglia L, Adamo V,
Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N
and Russo A: Driver mutations and differential sensitivity to
targeted therapies: A new approach to the treatment of lung
adenocarcinoma. Cancer Treat Rev. 36 (Suppl 3):S21–S29.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Delmonte A, Burgio MA, Verlicchi A, Bronte
G, Cravero P, Ulivi P, Martinelli G and Crinò L: New generation
anaplastic lymphoma kinase inhibitors. Transl Lung Cancer Res. 8
(Suppl 3):S280–S289. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Stinchcombe TE: Targeted therapies for
lung cancer. Cancer Treat Res. 170:165–182. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Blackhall FH, Peters S, Bubendorf L, Dafni
U, Kerr KM, Hager H, Soltermann A, O'Byrne KJ, Dooms C, Sejda A, et
al: Prevalence and clinical outcomes for patients with ALK-positive
resected stage I to III adenocarcinoma: Results from the European
Thoracic Oncology Platform Lungscape Project. J Clin Oncol.
32:2780–2787. 2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH,
Tsai MF, Yu CJ, Yang CH and Yang PC: EML4-ALK translocation
predicts better outcome in lung adenocarcinoma patients with
wild-type EGFR. J Thorac Oncol. 7:98–104. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kim HR, Shim HS, Chung JH, Lee YJ, Hong
YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, et al: Distinct
clinical features and outcomes in never-smokers with nonsmall cell
lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Cancer. 118:729–739. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhou JX, Yang H, Deng Q, Gu X, He P, Lin
Y, Zhao M, Jiang J, Chen H, Lin Y, et al: Oncogenic driver
mutations in patients with non-small-cell lung cancer at various
clinical stages. Ann Oncol. 24:1319–1325. 2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gao Q, Li P, Jiang X, Zhan Z, Yan Q, Zhang
B and Huang C: Worse disease-free, tumor-specific, and overall
survival in surgically-resected lung adenocarcinoma patients with
ALK rearrangement. Oncotarget. 8:86066–86081. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shin SH, Lee H, Jeong BH, Choi YS, Shin
MH, Kim S, Han J, Lee KS, Shim YM, Kwon OJ and Kim H: Anaplastic
lymphoma kinase rearrangement in surgically resected stage IA lung
adenocarcinoma. J Thorac Dis. 10:3460–3467. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kim MH, Shim HS, Kang DR, Jung JY, Lee CY,
Kim DJ, Lee JG, Bae MK, Kim HR, Lim SM, et al: Clinical and
prognostic implications of ALK and ROS1 rearrangements in
never-smokers with surgically resected lung adenocarcinoma. Lung
Cancer. 83:389–395. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li P, Gao Q, Jiang X, Zhan Z, Yan Q, Li Z
and Huang C: Comparison of clinicopathological features and
prognosis between ALK rearrangements and EGFR mutations in
surgically resected early-stage lung adenocarcinoma. J Cancer.
10:61–71. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Seto K, Kuroda H, Yoshida T, Sakata S,
Mizuno T, Sakakura N, Hida T, Yatabe Y and Sakao Y: Higher
frequency of occult lymph node metastasis in clinical N0 pulmonary
adenocarcinoma with ALK rearrangement. Cancer Manag Res.
10:2117–2124. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang P, Kulig K, Boland JM,
Erickson-Johnson MR, Oliveira AM, Wampfler J, Jatoi A, Deschamps C,
Marks R, Fortner C, et al: Worse disease-free survival in
never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol.
7:90–97. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sun JM, Lira M, Pandya K, Choi YL, Ahn JS,
Mao M, Han J, Park K, Ahn MJ and Kim J: Clinical characteristics
associated with ALK rearrangements in never-smokers with pulmonary
adenocarcinoma. Lung Cancer. 83:259–264. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fukui T, Yatabe Y, Kobayashi Y, Tomizawa
K, Ito S, Hatooka S, Matsuo K and Mitsudomi T: Clinicoradiologic
characteristics of patients with lung adenocarcinoma harboring
EML4-ALK fusion oncogene. Lung Cancer. 77:319–325. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Paik JH, Choi CM, Kim H, Jang SJ, Choe G,
Kim DK, Kim HJ, Yoon H, Lee CT, Jheon S, et al: Clinicopathologic
implication of ALK rearrangement in surgically resected lung
cancer: A proposal of diagnostic algorithm for ALK rearranged
adenocarcinoma. Lung Cancer. 76:403–409. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Mizuno T, Arimura T, Kuroda H, Sakakura N,
Yatabe Y and Sakao Y: Current outcomes of postrecurrence survival
in patients after resection of non-small cell lung cancer. J Thorac
Dis. 10:1788–1796. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lee JK, Park HS, Kim DW, Kulig K, Kim TM,
Lee SH, Jeon YK, Chung DH, Heo DS, Kim WH and Bang YJ: Comparative
analyses of overall survival in patients with anaplastic lymphoma
kinase-positive and matched wild-type advanced nonsmall cell lung
cancer. Cancer. 118:3579–3586. 2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Tantraworasin A, Lertprasertsuke N,
Kongkarnka S, Euathrongchit J, Wannasopha Y and Saeteng S:
Retrospective study of ALK rearrangement and clinicopathological
implications in completely resected non- small cell lung cancer
patients in Northern Thailand: Role of screening with D5F3
antibodies. Asian Pac J Cancer Prev. 15:3057–3063. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tao H, Cai Y, Shi L, Tang J and Liu Z,
Wang Z, Bai L and Liu Z: Analysis of clinical characteristics and
prognosis of patients with anaplastic lymphoma kinase-positive and
surgically resected lung adenocarcinoma. Thorac Cancer. 8:8–15.
2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jin Y, Chen Y, Yu X and Shi X: A
real-world study of treatment patterns and survival outcome in
advanced anaplastic lymphoma kinase-positive non-small-cell lung
cancer. Oncol Lett. 15:8703–8710. 2018.PubMed/NCBI View Article : Google Scholar
|
